Raynovent Announces Completion of Phase 1 Clinical Trial of Category 1 Drug ZSP1273.

Previous:Raynovent Announces Receiving of Certificate of Invention Patent in Canada

Next:Raynovent Announces Acceptance of IND Application of a Category 1 Drug, ZSP0678 for NASH Indication.